5i3b: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='5i3b' size='340' side='right'caption='[[5i3b]], [[Resolution|resolution]] 2.20Å' scene=''> | <StructureSection load='5i3b' size='340' side='right'caption='[[5i3b]], [[Resolution|resolution]] 2.20Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5i3b]] is a 2 chain structure with sequence from [ | <table><tr><td colspan='2'>[[5i3b]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Priestia_megaterium Priestia megaterium]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5I3B OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5I3B FirstGlance]. <br> | ||
</td></tr><tr id=' | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.2Å</td></tr> | ||
<tr id=' | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=HQE:BENZENE-1,4-DIOL'>HQE</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5i3b FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5i3b OCA], [https://pdbe.org/5i3b PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5i3b RCSB], [https://www.ebi.ac.uk/pdbsum/5i3b PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5i3b ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | |||
[https://www.uniprot.org/uniprot/B2ZB02_PRIMG B2ZB02_PRIMG] | |||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 24: | Line 26: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Adir | [[Category: Priestia megaterium]] | ||
[[Category: Deri | [[Category: Adir N]] | ||
[[Category: Fishman | [[Category: Deri B]] | ||
[[Category: Kanteev | [[Category: Fishman A]] | ||
[[Category: Kanteev M]] | |||
Latest revision as of 11:21, 23 August 2023
Crystal Structure of tyrosinase from Bacillus megaterium with configuration B of hydroquinone inhibitor in the active siteCrystal Structure of tyrosinase from Bacillus megaterium with configuration B of hydroquinone inhibitor in the active site
Structural highlights
FunctionPublication Abstract from PubMedTyrosinases are responsible for melanin formation in all life domains. Tyrosinase inhibitors are used for the prevention of severe skin diseases, in skin-whitening creams and to avoid fruit browning, however continued use of many such inhibitors is considered unsafe. In this study we provide conclusive evidence of the inhibition mechanism of two well studied tyrosinase inhibitors, KA (kojic acid) and HQ (hydroquinone), which are extensively used in hyperpigmentation treatment. KA is reported in the literature with contradicting inhibition mechanisms, while HQ is described as both a tyrosinase inhibitor and a substrate. By visualization of KA and HQ in the active site of TyrBm crystals, together with molecular modeling, binding constant analysis and kinetic experiments, we have elucidated their mechanisms of inhibition, which was ambiguous for both inhibitors. We confirm that while KA acts as a mixed inhibitor, HQ can act both as a TyrBm substrate and as an inhibitor. The unravelling of the complex pattern of tyrosinase inhibition.,Deri B, Kanteev M, Goldfeder M, Lecina D, Guallar V, Adir N, Fishman A Sci Rep. 2016 Oct 11;6:34993. doi: 10.1038/srep34993. PMID:27725765[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||